Cheers ttppxx. Yeah all fair enough but it stands to reason that...

Cheers ttppxx.

Yeah all fair enough but it stands to reason that with dose escalation the highest tolerated dose cohort is going to be the one that the OS assessment will be based on.

I'm not saying PSA isn't an indication of efficacy; I'm saying that comparing the small molecule approach with the antibody on the basis of PSA response is fraught.

Overall survival benefit of TLX591 when compared to Pluvicto shows that.

But even if you discount those figures;
Pluvicto elicited a higher PSA reduction but shorter PFS.

So obviously initial PSA reduction is not a reliable predictor of OS when two different targeting modalities are used.

Conversely I expect it to be much more reliable when comparing Cu67 to Pluvicto.

Here's hoping we continue to get good numbers here and soon, to halt the slide.

I won't be buying any more until we see what happens with the ASX200 in march.

And with what i posted about the 18 month post treatment, I clearly indicated that the median survival was not assured yet with my comment on outliers.

Cheers